Janux Therapeutics (JANX) Free Cash Flow (2020 - 2026)

Janux Therapeutics (JANX) has reported Free Cash Flow for 7 consecutive years, with -$12.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 25.53% year-over-year to -$12.6 million; the TTM figure through Mar 2026 stood at -$77.6 million (down 68.46% YoY), while the FY2025 annual figure was -$82.0 million, down 85.47% from the prior year.
• Free Cash Flow improved to -$12.6 million in Q1 2026 per JANX's latest filing, from -$27.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$2.0 million in Q3 2024 and bottomed at -$27.3 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$13.8 million across 5 years, with a median of -$12.6 million in 2026.
• Annual changes were most pronounced in 2024 — Free Cash Flow jumped 83.49% — and 2025, when it plunged 553.66%.
• Janux Therapeutics' Free Cash Flow stood at -$12.2 million in 2022, then increased by 14.8% to -$10.4 million in 2023, then plunged by 63.77% to -$17.1 million in 2024, then slumped by 60.21% to -$27.3 million in 2025, then surged by 53.86% to -$12.6 million in 2026.
• Business Quant data shows JANX's Free Cash Flow at -$12.6 million in Q1 2026, -$27.3 million in Q4 2025, and -$12.9 million in Q3 2025.